New York, USA, April 09, 2025 (GLOBE NEWSWIRE) -- Sodium Channel Blockers Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight The ...

Burlingame, March 07, 2024 (GLOBE NEWSWIRE) -- CoherentMI published a report, titled, Global Sodium Channel Blockers Market was valued at US$ 5.64 Billion in the year 2023 and is anticipated to reach ...

(MENAFN- GlobeNewsWire - Nasdaq) The sodium channel blockers market presents opportunities in treating conditions like arrhythmias, epilepsy, and neuropathic pain due to their action on sodium ...

South Korea’s SK Biopharmaceuticals Co. Ltd. and Shanghai-based Ignis Therapeutic Co. Ltd. signed a ₩804 billion (US$58 million) licensing deal on April 18, granting the latter global rights to a ...

Cystic fibrosis patients may benefit from a new therapy that increases airway hydration, preventing the buildup of mucous, which is a key factor in the disease. Cystic fibrosis patients may benefit ...

At present, it is not known whether the unexpected observations of worsening following withdrawal of phenytoin and carbamazepine in a mouse model of MS can be extrapolated to other models of MS, to ...

Several studies examining the use of sodium-channel blockers in patients with multiple sclerosis are currently underway. Questions about the long-term effects of these agents in neuroinflammatory ...

Dublin, Oct. 22, 2025 (GLOBE NEWSWIRE) -- The "Sodium Channel Blockers - Pipeline Insight, 2025" has been added to ResearchAndMarkets.com's offering. The "Sodium Channel Blockers - Pipeline Insight, ...

Nat Clin Pract Neurol. 2008;4(3):159-169. Despite the fact that phenytoin has been used successfully in the past to treat positive symptoms in patients with MS, the investigators at Yale University ...

ATS 2009, SAN DIEGO—Cystic fibrosis patients may benefit from a new therapy that increases airway hydration, preventing the buildup of mucous, which is a key factor in the disease, according to ...